GLADDEN Longevity Previously called as APEX HHPLO and CytoSolve deliver in silico modeling of molecular hydrogen to predict multi-pathway suppression of inflammatory pain mediators.

Partner Description

APEX HHPLO
APEX HHPLO develops molecular hydrogen small-molecule products designed to diffuse systemically and permeate cellular compartments, supporting inflammation-centered therapeutic applications.

Challenge

Inflammatory pain is driven by interconnected biochemical networks spanning enzyme induction, lipid mediator production, and downstream nociceptor sensitization. For molecular hydrogen—despite rapid diffusion into membranes, cytosol, mitochondria, and nuclei—its mechanism-based efficacy in inflammatory pain is difficult to establish because:

  • The pain phenotype emerges from multiple coupled pathways, not a single target.
  • Evidence is often distributed across siloed pathway studies, limiting end-to-end interpretation.
  • Translating molecular effects into predicted changes in clinically relevant mediators requires a systems-level, quantitative framework.

How CytoSolve® Helped

CytoSolve® applied its computational systems biology platform to build an in silico, mechanistic model of inflammatory pain and simulate the effects of molecular hydrogen across interacting pathways.

The modeling workflow included:

  • Pathway selection and scoping: CytoSolve identified three governing biomolecular pathways implicated in inflammatory pain and responsive to molecular hydrogen:
    • COX-2 Production Pathway
    • Arachidonic Acid Metabolism Pathway
    • PGE2-Induced TRPV1 and CGRP Synthesis Pathway
  • Mechanistic mathematical model construction: Each pathway was encoded as an individual mathematical model capturing relevant molecular interactions, regulatory structure, and dynamic relationships.
  • Pre-integration validation: Each pathway model was validated prior to coupling, supporting biological plausibility and internal consistency before system-level analysis.
  • Integrated in silico simulation: The validated pathway models were integrated within CytoSolve to form an end-to-end computational representation of inflammatory pain, enabling prediction of system-level outcomes produced by pathway-level perturbations from molecular hydrogen.

Key Benefits Realized

  • Created an in silico framework connecting upstream inflammatory biochemistry to downstream nociceptor sensitization outputs.
  • Enabled pathway-resolved mechanistic attribution of molecular hydrogen effects across COX-2 induction, arachidonic acid metabolism, and PGE2-driven signaling.
  • Produced validated, interoperable mathematical models that can be extended as new biology or hypotheses emerge.
  • Generated actionable predictions for pain-relevant biomarkers to guide experimental prioritization and therapeutic positioning.
  • Supported rapid evaluation of a broadly diffusing small molecule using a scalable computational approach.

Outcome

The integrated CytoSolve in silico analysis predicted that molecular hydrogen produces a therapeutic anti-inflammatory pain effect by downregulating COX-2, lowering PGE2, and reducing downstream nociceptor sensitization mediators TRPV1 and CGRP. Together, these predicted shifts indicate a system-level attenuation of inflammatory pain signaling and provide a mechanistic rationale for molecular hydrogen’s potential benefit in inflammation-associated pain indications.